Mikhail A Chafeev

This inventor holds 29 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Therapeutic Compounds. Top assignees: Xenon Pharmaceuticals Inc., Abbvie Inc., Pramana Pharmaceuticals Inc.. Active years: 2002-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikhail A Chafeev. Retrieved from https://idiyas.com/inventor/mikhail-a-chafeev

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 7)

% Patents Active = 34.5

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 6.1

ph-index = 11

Forward Citations = 332(Granted Patents)

Location History:

Vancouver, CA (2002 - 2013)
Himki, RU (2013)
Abbott Park, IL (US) (2016)
Burnaby, CA (2010 - 2017)
Toronto, CA (2018)
Khimki, RU (2014 - 2021)
Kiev, UA (2022)

Company Filing History:

20 out of 110

Xenon Pharmaceuticals Inc.

Pramana Pharmaceuticals Inc.

patents

4. 1 out of 6

Dermira (Canada), Inc.

patents

5. 1 out of 6

Kinetek Pharmaceuticals, Inc.

Valocor Therapeutics, Inc.

patents

Years Active: 2002-2022

Loading Chart...

Areas of Expertise:

Therapeutic Agents

Spiro-Oxindole Compounds

G Protein-Coupled Receptor

Benzo[d][1,3]Oxathiole

Thiazoles

Cyanoguanidines

Hydrazonopyrazole Derivatives

Pyridazine Derivatives

Synthetic Methods

Enantiomers

Combination Therapy

Spiroheterocyclic Compounds

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11358956 - Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 (2022-06-14),

2. 10906894 - Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 (2021-02-02),

3. 10233179 - Thiazoles and uses thereof (2019-03-19),

4. 10112911 - Substituted cyanoguanidines as oral anti-virals (2018-10-30),

5. 9695185 - Synthetic methods for spiro-oxindole compounds (2017-07-04),

6. 9630929 - Benzenesulfonamide compounds and their use as therapeutic agents (2017-04-25),

7. 9480677 - Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents (2016-11-01),

8. 9458178 - Spiro-oxindole compounds and their use as therapeutic agents (2016-10-04),

9. 9447051 - Diaminopyrimidines and uses thereof (2016-09-20),

10. 9260446 - Synthetic methods for spiro-oxindole compounds (2016-02-16),

11. 8916580 - Spiro-oxindole compounds and their use as therapeutic agents (2014-12-23),

12. 8883840 - Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents (2014-11-11),

13. 8742109 - Synthetic methods for spiro-oxindole compounds (2014-06-03),

14. 8466188 - Use of spiro-oxindole compounds as therapeutic agents (2013-06-18),

15. 8450358 - Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents (2013-05-28),

Title: **Mikhail A. Chafeev: Innovator in Pharmaceutical Patents**

Introduction

Mikhail A. Chafeev, based in Vancouver, CA, is a prominent inventor in the pharmaceutical field, holding a remarkable portfolio of 29 patents. His innovative contributions focus primarily on the development of compounds that have significant therapeutic potential, particularly in the area of metabolic disorders.

Latest Patents

Chafeev's latest patents include groundbreaking compounds that contain polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide. These compounds have been identified as agonists of G protein-coupled receptor 119 (GPR119), which play a vital role in the treatment of diseases and conditions associated with GPR119 dysregulation, such as Type 2 diabetes mellitus and related metabolic disorders. The intricate structure of these compounds allows for various combinations of functional groups, making them versatile for future therapeutic applications.

Career Highlights

Throughout his career, Mikhail Chafeev has made significant strides in the pharmaceutical industry, having worked with renowned companies such as Xenon Pharmaceuticals Inc. and AbbVie Inc. His expertise and innovative mindset have led to the development of novel pharmaceutical solutions that have the potential to improve patient outcomes significantly.

Collaborations

Chafeev's collaborative efforts have also been instrumental in his success as an inventor. He has worked alongside talented colleagues such as Sultan Chowdhury and Jianmin Fu, fostering an environment where innovation can thrive. Together, they contributed to advancements in the field of biochemistry and pharmacology.

Conclusion

Mikhail A. Chafeev exemplifies the role of a dedicated inventor in the pharmaceutical industry, with a strong track record of patents that address critical health challenges. His contributions not only reflect his expertise but also highlight the importance of continuous innovation in improving healthcare solutions for diseases like Type 2 diabetes. As he continues to forge a path in research and development, the impact of his work will undoubtedly resonate in the field for years to come.

Profile summary based on public USPTO records.